Crescent Biopharma vs Prelude Therapeutics
CBIO and PRLD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CBIO and PRLD compare
Crescent Biopharma is the larger company, worth 1.8 times as much as Prelude Therapeutics ($548M against $302M).
Prelude Therapeutics scores higher on the StockData Score (8 against 7 for Crescent Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CBIO | PRLD |
|---|---|---|
| Size and price | ||
| Market cap | $548M | $302M |
| Share price | $14.76 | $3.78 |
| Change, 1 year | 12.5% | 200% |
| Change, 5 years | −92.2% | −73.9% |
| Beta (5Y) | 1.63 | 1.24 |
| Employees | 44 | 79 |
| StockData Score | ||
| Total score | 7 | 8 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 1 |
| Performance score | 0 | 1 (better) |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 13.5× |
| P/B | 3.4× | 2.3× (better) |
| FCF yield | −13.4% | −11.0% (better) |
| Fair value | – | $2.16 |
| Margin of safety | – | −74.8% |
| Growth | ||
| Revenue growth (TTM) | – | 220% |
| Revenue growth, 5Y average | 1.3% | – |
| Profitability | ||
| Operating margin | – | −301% |
| Net margin | – | −270% |
| FCF margin | – | −148% |
| Return on equity | −63.5% | −57.7% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 9.66 (better) | 4.07 |
| Altman Z-score | 13.19 (better) | −2.29 |
| Piotroski F-score | – | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 79.7% | 62.2% |
| Held by insiders | 38.6% | 40.5% |
| Insider net buying, 12 months | $29.1M (better) | $25.0M |
| Short interest, % of float | 18.3% | 8.8% |
Go deeper
- CBIO stock overview
- CBIO income statement
- CBIO valuation and score
- PRLD stock overview
- PRLD income statement
- PRLD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.